RAC

RACURA FPO [RAC]
Racura Oncology Ltd operates as a clinical-stage biopharmaceutical company in Australia. It develops RC220, a formulation of (E,E)-bisantrene, which is in Phase III clinical trial for the treatment of acute myeloid leukemia; Phase Ia/b clinical trial for the treatment of epidermal growth factor receptor-mutated non-small cell lung cancer; and Phase Ia/b clinical trial for the treatment of solid tumor cancers. The company was formerly known as Race Oncology Limited and changed its name to Racura Oncology Ltd in December 2025. Racura Oncology Ltd was incorporated in 2011 and is headquartered in Sydney, Australia.
Healthcare · ASX Small Cap
$2.1000 -1.4%

Updated 9 Sep 2026 · Signals refresh every scan

Appeared in 2 consecutive scansFirst seen: 2026-02-25
Get alerts when RAC triggers a new signal
Free watchlist with daily scans for 2,200+ ASX stocks
Track RAC — Free

Active Signals

Bullish Signals

  • Strong cash runway (17 quarters)
  • Very high P/S ratio (145.1x)
  • EPS estimates revised downward (-10pts)
  • Near 52-week low (17% of range)
  • Sentiment is mixed — no strong consensus either way
  • Altman Z-Score grey zone (1.84, low-confidence approx)
  • RBA hiking (-3pts)

Risk Signals

  • MACD crossed bearish — momentum is fading
  • Below the 200-day average — the long-term trend is still working against it
  • Revenue declining (-12%)
  • Piotroski F-Score weak (3/9, low-confidence approx)
  • Not enough chatter to gauge sentiment — defaulting to neutral
  • Long-term momentum is negative — down 42% over the past year
  • Revenue declining at -12% — the top line is shrinking

Expected next for RAC

10 Nov 2026Quarterly Cash Flow Report (4C)Estimated from past filings
Window: 3 Nov to 17 Nov
The last 3 moved RAC -2.2% on the day, on average — an observation, not a guide to what happens next.
Each date is labelled with how it is known. A date estimated from past filings is inferred from this company's own filing rhythm — it is not a confirmed date and not a statement about what the company intends to do. See the whole ASX calendar →

Recent Catalysts

LOW RC220 MYC-silencing data to be presented FCS 26 conference
NONE Racura Oncology Adelaide Investor Briefing
NONE Notification regarding unquoted securities - RAC
NONE CPACS Trial Opens for RC220 Patient Enrolment in Korea

Recent ASX Announcements

2026-09-07 RC220 MYC-silencing data to be presented FCS 26 conference
2026-09-03 Racura Oncology Adelaide Investor Briefing
2026-09-01 Notification regarding unquoted securities - RAC
2026-08-31 CPACS Trial Opens for RC220 Patient Enrolment in Korea PRICE SENSITIVE
2026-08-25 Corporate Governance Statement

Key Metrics

$407.8M
Market Cap
75K
Avg Volume
1.4x
Vol Ratio
$1.49 — $4.90
52-Week Range
0.0%
Short Interest
N/A
Cash Runway
-42.3%
ROE
N/A
Profit Margin

CANSLIM Analysis

FactorRatingDetail
CCurrent EPSfailEPS Growth: 0%
AAnnual EarningsfailCAGR: 0%
NNew Highs / Catalystsneutral
SSupply & DemandneutralFloat: 70%
LLeader vs LaggardlaggardRS: -7
IInstitutional SponsorshipweakInst: 0%
MMarket DirectionneutralNeutral

Sector: Healthcare

110 tickers in this sector

View all Healthcare signals →Browse all ASX tickers A–Z →
Related Tickers
NUZ +37.1%IPD +20.0%HIQ +16.7%AVE +15.0%CVB +11.1%
Compare:RAC vs NUZRAC vs IPDRAC vs HIQ
Share this analysis

Track RAC and 2,200+ ASX stocks

Get free access to Scout's AI-powered dashboard with daily scans, watchlist alerts, and exit management for every ASX small cap.

Open Dashboard — Free Free Screener
No credit card required